convent
influenza
vaccin
need
design
manufactur
yearli
howev
occasion
provid
poor
protect
owe
antigen
mismatch
henc
urgent
need
develop
univers
vaccin
influenza
viru
use
nucleoprotein
np
extracellular
domain
matrix
protein
gene
influenza
viru
construct
four
recombin
vaccinia
virusbas
influenza
vaccin
carri
np
fuse
one
four
copi
gene
differ
order
recombin
vaccinia
virus
use
immun
balbc
mice
humor
cellular
respons
measur
immun
mice
challeng
influenza
viru
apuerto
npspecif
humor
respons
elicit
mice
immun
recombin
vaccinia
virus
carri
fulllength
np
robust
humor
respons
elicit
mice
immun
recombin
vaccinia
virus
carri
multipl
copi
recombin
virus
elicit
npand
cellular
immun
respons
mice
immun
induc
remark
higher
level
cytokin
specif
furthermor
immun
provid
highest
crossprotect
mice
challeng
mld
therefor
crossprotect
potenti
correl
np
humor
cellular
immun
respons
induc
express
fusion
antigen
fulllength
np
preced
four
repeat
result
suggest
ration
fusion
np
multipl
antigen
critic
toward
induc
protect
immun
respons
fusion
antigen
may
employ
develop
univers
influenza
vaccin
season
influenza
acut
respiratori
infecti
diseas
caus
seriou
health
problem
season
influenza
epidem
caus
influenza
b
virus
result
million
sever
case
death
worldwid
adult
children
suffer
flu
annual
world
health
organ
season
influenza
virus
undergo
antigen
drift
make
convent
season
vaccin
ineffect
vaccin
strain
mismatch
epidem
strain
therefor
season
influenza
vaccin
must
updat
regularli
effect
prevent
influenza
product
time
convent
influenza
vaccin
lengthi
take
month
obtain
vaccin
strain
use
convent
reassort
technolog
revers
genet
technolog
follow
sever
month
largescal
expans
influenza
vaccin
use
ampl
suppli
specif
pathogenfre
spf
chicken
embryo
gener
influenza
vaccin
product
take
month
predict
epidem
strain
ultim
product
vaccin
emanuel
wertheim
effect
prevent
influenza
new
vaccin
warrant
induc
crossprotect
longlast
immun
respons
erbeld
electron
np
extracellular
domain
matrix
protein
induc
crossprotect
influenza
viru
show
promis
candid
antigen
develop
broadspectrum
influenza
vaccin
erbeld
et
al
zhang
et
al
kui
et
al
previous
express
fusion
protein
np
escherichia
coli
show
immun
formul
aluminum
hydroxid
gel
protect
mice
lethal
challeng
heterolog
influenza
viru
therefor
vaccin
recombin
fusion
protein
promis
strategi
develop
univers
influenza
vaccin
howev
new
express
system
requir
optim
npand
vaccin
vaccinia
viru
tiantan
strain
develop
china
vaccin
agent
smallpox
document
fenner
et
al
strain
use
inocul
sever
individu
year
play
key
role
erad
smallpox
china
ruan
tiantan
strain
favor
gene
vector
vaccin
characterist
includ
power
multipl
capac
wide
host
rang
high
capac
insert
foreign
gene
noncarcinogen
induct
longlast
immun
use
tk
gene
system
tiantan
strain
vaccinia
viru
develop
success
viral
vector
variou
vaccin
applic
ruan
sever
acut
respiratori
syndrom
coronaviru
vaccin
yan
et
al
develop
recombin
vaccinia
virus
base
np
influenza
viru
wang
et
al
wang
et
al
sever
npbase
recombin
vaccinia
virus
induc
protect
immun
respons
balbc
mice
develop
vaccin
broader
protect
construct
recombin
vaccinia
virus
express
variou
combin
np
exhibit
maxim
antigen
balbc
mice
immun
recombin
virus
measur
npand
humor
cellular
immun
respons
well
protect
effect
lethal
challeng
heterolog
influenza
viru
materi
bgal
monoclon
antibodi
np
monoclon
antibodi
purchas
santa
cruz
biotechnolog
santa
cruz
ca
usa
monoclon
antibodi
alexa
fluor
goat
antimous
polyclon
antibodi
abcam
cambridg
usa
bd
cytometr
bead
array
cba
mous
cytokin
kit
purchas
bd
franklin
lake
nj
usa
peptid
rliqnsltiermvl
th
epitop
tyqrtralv
ctl
epitop
pool
peptid
peptid
residu
synthes
beij
scilight
biotechnolog
ltd
co
beij
china
vaccinia
viru
tiantan
strain
influenza
viru
apuerto
use
studi
vaccinia
viru
tiantan
strain
amplifi
titrat
primari
chicken
embryo
fibroblast
cef
influenza
viru
propag
chicken
embryo
h
allanto
fluid
collect
store
use
mous
lethal
dose
mld
titer
influenza
viru
assess
balbc
mice
conduct
challeng
experi
plasmid
contain
two
dna
fragment
tkl
tkr
deriv
vaccinia
viru
tiantan
strain
facilit
homolog
recombin
vaccinia
viru
host
cell
two
homolog
arm
late
promot
vaccinia
viru
regul
lacz
gene
earlyl
promot
vaccinia
viru
regul
target
gene
linear
bamh
restrict
enzym
site
immedi
downstream
promot
treat
calf
intestin
alkalin
phosphatas
plasmid
contain
fusion
gene
fulllength
np
amino
acid
succeed
amino
acid
influenza
viru
np
fusion
gene
refer
amplifi
plasmid
polymeras
chain
reaction
pcr
introduc
bamh
site
end
digest
bamh
insert
linear
plasmid
result
plasmid
carri
orient
promot
design
plasmid
np
gene
amplifi
respect
fuse
preced
np
pcr
gener
fusion
gene
dna
fragment
contain
four
copi
amplifi
plasmid
fuse
terminu
fulllength
np
gene
pcr
result
fusion
gene
dna
fragment
contain
four
copi
also
fuse
terminu
np
gene
truncat
end
refer
np
encod
amino
acid
amplifi
plasmid
pcr
result
fusion
gene
name
fusion
gene
engin
bamh
site
end
pcr
clone
linear
describ
result
plasmid
respect
recombin
vaccinia
virus
gener
via
homolog
recombin
describ
wang
et
al
briefli
cef
infect
vaccinia
viru
tiantan
strain
multipl
infect
follow
transfect
recombin
plasmid
contain
fusion
gene
np
subsequ
recombin
vaccinia
virus
screen
bluewhit
select
viral
dna
isol
recombin
vaccinia
viru
confirm
presenc
fusion
gene
pcr
sequenc
pcr
product
confirm
recombin
vaccinia
virus
produc
larg
scale
cef
control
recombin
vaccinia
viru
gener
use
method
empti
vector
confirm
express
np
recombin
vaccinia
virus
use
indirect
immunofluoresc
cell
grown
cultur
plate
infect
strain
viru
plaqueform
unit
pfu
well
h
post
infect
cell
fix
paraformaldehyd
express
bgal
np
confirm
use
mous
monoclon
antibodi
mab
bgal
mous
mab
influenza
viru
mous
mab
influenza
viru
np
signal
visual
use
alexa
fluor
goat
antimous
spf
femal
balbc
week
old
mice
purchas
beij
vital
river
laboratori
anim
technolog
co
ltd
beij
china
mice
bred
spf
condit
institut
laboratori
anim
scienc
chines
academi
medic
scienc
peke
union
medic
colleg
beij
china
mice
randomli
group
micegroup
inocul
intramuscularli
pfu
recombin
vaccinia
virus
week
week
bilater
gastrocnemiu
without
use
reagent
equip
ten
day
second
immun
three
mice
group
retroorbit
bled
sacrif
spleen
remov
asept
ground
siev
spleen
mononuclear
cell
smnc
obtain
describ
wang
et
al
cellular
immun
respons
induc
mice
evalu
enzymelink
immunospot
elispot
assay
bd
cba
mous
cytokin
kit
accord
manufactur
instruct
peptid
pool
peptid
use
elispot
cba
assay
sera
separ
centrifug
serum
igg
titer
determin
two
week
second
immun
mice
anesthet
use
sodium
pentobarbit
mgml
dose
mgkg
bodi
weight
subsequ
mice
group
challeng
time
mous
lethal
dose
mld
intranas
weight
loss
mortal
monitor
daili
week
challeng
mice
lost
initi
weight
euthan
record
die
statist
analysi
perform
use
spss
ver
spss
inc
chicago
il
usa
prism
ver
graphpad
inc
la
jolla
ca
usa
log
convers
perform
antibodi
titer
differ
antibodi
titer
elispot
cba
result
among
group
analyz
use
oneway
anova
pair
test
logrank
test
use
analyz
differ
weight
loss
curv
surviv
rate
curv
respect
differ
p
valu
consid
statist
signific
gener
fusion
antigen
highest
potenc
induc
crossprotect
design
varieti
fusion
antigen
configur
adjust
fusion
order
np
increas
copi
number
truncat
length
np
np
gene
fragment
influenza
viru
join
creat
use
pcr
fig
amplifi
fusion
gene
fragment
clone
plasmid
regul
earlyl
promot
result
plasmid
confirm
restrict
endonucleas
digest
dna
sequenc
data
shown
confirm
plasmid
transfect
cef
infect
vaccinia
viru
tiantan
strain
facilit
homolog
dna
recombin
plasmid
viral
genom
dna
recombin
vaccinia
virus
screen
bluewhit
select
vaccinia
viru
dna
extract
amplifi
target
gene
fragment
use
pcr
insert
target
gene
confirm
sequenc
pcr
product
cell
infect
recombin
vaccinia
virus
express
target
protein
np
identifi
immunofluoresc
select
marker
bgalactosidas
bgal
express
similar
level
cell
infect
recombin
vaccinia
virus
except
control
viru
recombin
vaccinia
viru
express
np
infect
cell
seem
show
lower
express
truncat
np
recombin
vaccinia
virus
carri
fulllength
np
gene
fig
flow
cytometri
analysi
target
protein
express
show
similar
result
western
blot
analysi
confirm
target
protein
express
expect
molecular
weight
supplementari
materi
character
immunogen
fusion
antigen
express
recombin
vaccinia
virus
five
group
balbc
mice
immun
pfu
recombin
vaccinia
viru
week
ten
day
second
immun
sera
taken
measur
antibodi
titer
spleen
remov
asept
measur
cellular
immun
respons
mice
immun
recombin
vaccinia
viru
show
strong
antibodi
respons
np
lower
titer
antibodi
fig
induc
strong
antibodi
respons
np
induc
strong
humor
immun
respons
np
elispot
analysi
fig
reveal
induc
spotform
cell
sfc
sfc
induc
significantli
sfc
p
p
also
induc
significantli
sfc
control
viru
nevertheless
signific
differ
compar
except
control
viru
recombin
vaccinia
viru
seem
induc
cellular
immun
respons
fig
howev
sfc
induc
significantli
induc
control
viru
p
p
cytokin
measur
fig
show
pool
peptid
stimul
smnc
secret
sever
cytokin
includ
interleukin
il
tumor
necrosi
factor
howev
immun
induc
significantli
higher
level
cytokin
control
stimul
pool
peptid
assess
protect
efficaci
recombin
vaccinia
virus
balbc
mous
model
two
week
second
immun
balbc
mice
challeng
mld
influenza
viru
weight
loss
surviv
rate
monitor
week
weight
loss
curv
fig
show
mice
immun
experienc
rapid
weight
loss
mice
die
day
postchalleng
mice
immun
also
experienc
rapid
weight
loss
sever
mice
die
soon
challeng
other
experienc
maximum
weight
loss
day
postchalleng
follow
gradual
recoveri
mice
immun
experienc
lowest
averag
weight
loss
among
group
observ
day
postchalleng
follow
rapid
recoveri
initi
bodi
weight
day
postchalleng
surviv
rate
result
fig
show
mice
immun
die
day
respect
postchalleng
contrast
mice
die
day
postchalleng
show
final
surviv
rate
mice
immun
die
day
postchalleng
final
surviv
rate
statist
analysi
show
mice
immun
significantli
highest
surviv
rate
mice
immun
also
significantli
higher
surviv
rate
remain
three
group
fig
extracellular
domain
highli
conserv
among
influenza
viru
subtyp
et
al
zebede
lamb
thu
adopt
target
antigen
develop
univers
influenza
vaccin
present
studi
singl
induc
poor
humor
respons
fig
four
tandem
repeat
induc
robust
antibodi
respons
fig
lead
much
stronger
crossprotect
group
heterosubtyp
influenza
viru
challeng
fig
prove
robust
immun
respons
induc
multipl
copi
zhang
et
al
zhao
et
al
zhou
et
al
enhanc
fusion
appropri
protein
carrier
et
al
zhao
et
al
ebrahimi
et
al
alvarez
et
al
schotsaert
et
al
data
suggest
antibodi
cellular
respons
play
import
role
protect
favor
induc
protect
immun
respons
specif
antibodi
may
play
protect
role
antibodydepend
cellmedi
cytotox
adcc
although
could
neutral
influenza
viru
kim
et
al
lee
et
al
besid
specif
cellular
immun
respons
may
stimul
cell
protect
anim
adlermoor
et
al
np
also
use
target
antigen
develop
univers
influenza
vaccin
li
et
al
wang
et
al
nahampun
et
al
lei
et
al
zheng
et
al
present
studi
truncat
np
protein
lack
amino
acid
n
termin
amino
acid
c
termin
design
np
although
np
retain
middl
part
np
multipl
conserv
epitop
show
weaker
immunogen
compar
fulllength
np
fig
less
protect
experi
fig
vs
p
probabl
less
np
express
fig
middl
panel
suggest
fulllength
np
critic
toward
induc
protect
immun
least
balbc
mous
previou
research
prove
human
mab
influenza
np
play
import
role
fight
lowdos
infect
influenza
viru
fujimoto
et
al
np
might
exert
protect
effect
adcc
kui
et
al
hayward
et
al
present
studi
show
npspecif
antibodi
cellular
respons
play
import
role
protect
npspecif
antibodi
could
neutral
influenza
viru
howev
may
protect
anim
challeng
adcc
antibodydepend
cellular
phagocytosi
antibodydepend
complement
deposit
np
cellular
immun
respons
may
stimul
cell
protect
guo
et
al
lamer
et
al
relat
mechan
worthi
investig
humor
cellular
immun
respons
balbc
mice
immun
recombin
vaccinia
virus
mice
immun
intramuscularli
plaqueform
unit
recombin
vaccinia
virus
week
group
mice
immun
serv
neg
control
serum
obtain
three
mice
day
post
second
immun
analyz
enzymelink
immunoassay
elisa
presenc
igg
antibodi
specif
np
left
right
describ
materi
method
column
show
geometr
mean
antibodi
titer
bar
indic
confid
interv
group
n
mice
per
group
compar
result
two
group
shown
upper
tabl
ns
signific
p
p
p
oneway
anova
b
c
cellular
immun
respons
mice
immun
recombin
vaccinia
virus
cytokin
secret
stimul
spleen
mononuclear
cell
smnc
measur
enzymelink
immunospot
elispot
assay
b
mous
cba
kit
c
mice
treatment
group
sacrif
day
post
second
immun
smnc
separ
mous
spleen
sampl
lgml
left
b
middl
b
pool
peptid
right
b
c
use
stimul
elispot
cba
assay
stimul
h
number
smnc
produc
interferon
ifn
c
b
present
spotform
cell
sfc
smnc
column
show
averag
smnc
bar
indic
standard
deviat
group
line
two
group
indic
signific
differ
p
p
p
oneway
anova
furthermor
determin
whether
immunogen
fusion
antigen
influenc
order
np
data
show
induc
similar
antigenspecif
igg
respons
fig
vs
howev
induc
significantli
well
sfc
former
one
fig
vs
suggest
n
termin
fusion
antigen
favor
configur
induc
npand
cellular
immun
moreov
data
indic
four
copi
preced
np
robust
toward
induc
npand
humor
immun
respons
fig
vs
protect
fig
vs
addit
observ
immun
induc
significantli
higher
level
cytokin
mice
stimul
pool
peptid
fig
signific
progress
made
develop
influenza
vaccin
use
viral
vector
kim
et
al
li
et
al
tutykhina
et
al
dhanwani
et
al
sever
recombin
viral
vaccin
construct
base
modifi
vaccinia
viru
ankara
express
ha
np
antigen
coughlan
et
al
mullin
et
al
di
mario
et
al
altenburg
et
al
vaccinia
viru
tiantan
strain
develop
china
vaccin
smallpox
also
use
viral
vector
numer
studi
develop
recombin
viral
vaccin
studi
vaccinia
viru
tiantan
strain
use
construct
recombin
vaccinia
virus
express
fusion
antigen
differ
configur
recombin
vaccinia
viru
express
fulllength
np
fusion
antigen
induc
strong
crossprotect
lethal
heterosubtyp
challeng
mld
thu
regard
optim
one
among
four
construct
previou
studi
express
fusion
protein
e
coli
system
determin
immunogen
balbc
mice
howev
inconveni
time
consum
express
purifi
much
altern
moreov
imposs
express
target
antigen
e
coli
system
success
sometim
compar
e
coli
system
recombin
vaccinia
viru
system
characterist
high
multipl
capac
requir
purifi
protein
higheffici
determin
immunogen
target
antigen
anim
model
coughlan
et
al
mullin
et
al
fact
succeed
construct
determin
antigen
sever
fusion
antigen
np
effici
summari
immun
np
fusion
antigen
induc
npspecif
humor
cellular
immun
respons
also
increas
immun
togeth
led
superior
crossprotect
heterosubtyp
mld
conclud
crossprotect
potenti
correl
np
humor
cellular
immun
respons
induc
howev
recombin
contain
fulllength
np
could
induc
signific
neutral
antibodi
help
reduc
sever
durat
ill
therefor
necessari
introduc
conserv
bcell
epitop
ha
induc
enhanc
crossneutr
respons
protect
potenc
koday
et
al
futur
studi
focu
develop
univers
influenza
mice
monitor
daili
day
challeng
mice
weigh
daili
monitor
morbid
averag
weight
treatment
group
follow
durat
studi
percentag
origin
bodi
weight
calcul
base
averag
start
weight
group
day
b
surviv
rate
calcul
compar
among
group
ns
signific
p
p
p
vaccin
contain
multipl
antigen
induc
broad
neutral
respons
adcc
broad
cellular
immun
respons
